🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Tune in this Thursday, June 17th from 10am-12pm ET for a great webinar hosted by International Society of Liquid Biopsy featuring out very own VP of Science Policy, Mark! Watch the lively discussion and then find out more about our work on #ctDNA here: trib.al/mtPc6ES

Virtual PD-1 resistance workshop today from Kidney Cancer KCCure LUNGevity Foundation w/ awesome discussions #ToniRibas Brian Alexander on resistance to IO-based treatments & future trial designs. Primary vs acquired resistance from Toni & parachute analogy from Brian.

Excellent discussion with colleagues from #LCSM #kcsm #melanoma FDA Oncology & industry on trial design in cancers that have primary or acquired resistance to immunotherapy

We can't thank our fantastic TMB Harmonization Project partners enough! Representing stakeholders and institutions from across government, academia, diagnostics, industry, and more #TMB #WhatFriendsDoes friendsofcancerresearch.org/tmb

New publication out now in Journal of Biopharmaceutical Statistics co-authored by Friends of Cancer Research Mark “Exploring the Potential of External Control Arms created from Patient Level Data: A case study in non-small cell #lungcancer.” trib.al/dPjsLwG Medidata U.S. FDA Johns Hopkins University

Exciting data in Friends of Cancer Research study published in JCO Precision Oncology helps advance our understanding of #ctDNA and its potential use as an #endpoint in #oncology drug development to speed life-saving treatments to patients.

We are honored to receive the Patient-Centered Health Award from Regulatory Affairs Professionals Society

New perspective released by BLOODPAC. Proud to partner with an incredible organization and group of folks to highlight the need for collaboration and steps necessary to bring high-quality blood-based screening tests to patients.

Clinical trials are mind boggling complicated. We need to simplify trials says Rick Pazdur and FDA Commissioner at Friends of Cancer Research. FDA Oncology #OCE launching new initiative: Project Pragmatica. #FriendsAM22

Next up - panel 1 focused on applying lessons learned from the COVID-19 pandemic to advance clinical trial conduct. #FriendsAM22 Friends of Cancer Research

As this year-long journey is coming to an end, wanted to thank the Special Series co-editor Mark, Journal for ImmunoTherapy of Cancer editors Drs. Romero, Demaria and Fong, the amazing Journal for ImmunoTherapy of Cancer editorial team, Matthew Erickson and Andrea Kunz and Jennifer E. Fairman, CMI, FAMI for the series cover.

New publication announced featuring Friends of Cancer Research’s Mark “Liquid Biopsies Coming of Age: Biology, Emerging Technologies, and Clinical Translation.” Journal for ImmunoTherapy of Cancer #JITC Learn more: jitc.bmj.com/content/11/1/e…

New Journal for ImmunoTherapy of Cancer liquid biopsies publication series featuring Friends of Cancer Research’s Mark and Johns Hopkins Kimmel Cancer Center's Elsa Anagnostou addresses the state of the science of liquid biopsies to help map evidentiary gaps and opportunities. trib.al/AZKTZ8B #JITC @SITCancer

Check out our latest #JITC special series, "Liquid Biopsies Coming of Age: Biology, Emerging Technologies, and Clinical Translation," featuring review articles, viewpoint letters, & video abstracts. Edited by Elsa Anagnostou and Mark (Friends of Cancer Research). bit.ly/3YhLZza

Identifying new and accurate early endpoints can help support innovation and bring new therapies to patients safely and efficiently. Hillary Andrews, PhD presents data from the Friends of Cancer Research #ctMoniTR project indicating the promise of ctDNA as an early endpoint in cancer drug development

Wanted to thank all of the phenomenal scientists, clinicians & patient advocates as well as the Journal for ImmunoTherapy of Cancer editorial team that worked with Mark and me for over a year to deliver this special series on #liquidbiopsies jitc.bmj.com/content/11/1/e… Johns Hopkins Kimmel Cancer Center Friends of Cancer Research

The number of the Journal for ImmunoTherapy of Cancer #liquidbiopsy series contributors by far exceeds the character limit, thank you Kathi Apostolidis Nicola Normanno IQNPath ASBL @cancereu International Society of Liquid Biopsy Nick Semenkovich, MD PhD Peter B. Bach, MD @gameijer Claus Lindbjerg Andersen Nicholas Dracopoli Victor Velculescu Julia Beaver M JOSE SERRANO Lab (LB&Cancer Interception group) Aakash Desai, MD, MPH, FASCO

Our #TranslationalScience symposium continues with talks on #ctDNA and #MRD by Dustin Deming of UW Health | Carbone Cancer Center, Mark of Friends of Cancer Research, and Angie DeMichele, MD, MSCE, FASCO of Penn Medicine - Abramson Cancer Center. #TherapyOptimization

Countdown to 2024: #JITCTop10 - Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs bit.ly/3p7HElL Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) Patrick Forde Elad Sharon Dena Battle @DrMarc15 Mark

Friends’ Mark is attending ESGCT Annual Conference in #Rome discussing a framework for data extrapolation in cell & gene therapies, showing how innovative approaches can accelerate the development of next-gen #treatments. Friends #CGT portfolio: friendsofcancerresearch.org/cell-gene-ther…